Biotech Values

[DewDiligence]

Barron’s plug for PFE omits a relevant detail—if the AGN merger goes through, the deal will be fully taxable to US PFE shareholders and (if the deal closes less than one year from now) the tax hit will be at short-term rates:

http://www.barrons.com/articles/pfizer-is-attractive-with-or-without-allergan-1446267612